![GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System](/sites/default/files/styles/max_750x750/public/2023-06/AY1183-EN1-CMDS-0902-FNL-EDIT-1147x430_1.png.webp?itok=UY7IA14E)
Designed for the demands of TEVAR
Six key considerations to help you deliver optimal results.
Hemodynamic stability
![NO rapid pacing used in 93% of cases1](/sites/default/files/styles/max_750x750/public/2023-01/02-22755804-EN-CMDS-Infogfx-Web_500.jpg.webp?itok=CnxakVkP)
Unique oversizing window
Conformability
![Real world2 treatment* transection zero Type III endoleaks†, ruptures, device fractures, compressions, conversions](/sites/default/files/styles/max_750x750/public/2023-01/05-22755804-EN-CMDS-Infogfx-Web_500.jpg.webp?itok=-UmLb2Ou)
* GORE® TAG® Conformable Device.
† Endoleak requiring intervention. No endoleaks persisted past one month or required intervention.
- W. L. Gore & Associates. Observational Registry Characterizing the Performance and Feature Use of the GORE® TAG® Conformable Thoracic Stent Graft Featuring ACTIVE CONTROL System. NLM Identifier: NCT03286400. Published September 18, 2017. Updated December 17, 2020. Accessed February 23, 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT03286400
- GREAT is a prospective, observational, multicenter registry to actively track Gore commercial aortic endovascular device performance and associated patient outcomes in global markets with 10 years of follow-up. Data June 2017. Through 2-year follow-up. Transection n = 53.
241345600-EN